Trials / Completed
CompletedNCT07477756
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients Receiving Lutetium-177 Vipivotide Tetraxetan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,247 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.
Conditions
Timeline
- Start date
- 2024-09-04
- Primary completion
- 2025-03-14
- Completion
- 2025-03-14
- First posted
- 2026-03-17
- Last updated
- 2026-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07477756. Inclusion in this directory is not an endorsement.